Monday, 14 September 2026European Markets

CRCAM BRIE PIC2CCI And TINC Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - crcam brie pic2cci (crbp2.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
crcam brie pic2cci (crbp2.pa) €18.30 5.48% 4.04%
tinc (tinc.br) €12.10 4.52% 6.13%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. crcam brie pic2cci (crbp2.pa)

5.48% forward dividend yield and 4.04% return on equity

caisse régionale de crédit agricole mutuel brie picardie société coopérative provides a range of banking and financial products and services to individuals, farmers, professionals, businesses, and local authorities. it offers savings support comprising monetary, bonds, and securities; and life insurance investments, as well as housing and consumer loans; payment services; and property and casualty insurance, provident insurance products, and life insurance products. the company is headquartered in amiens, france. caisse régionale de crédit agricole mutuel brie picardie société coopérative operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam brie pic2cci has a trailing twelve months eps of €11.35.

pe ratio

crcam brie pic2cci has a trailing twelve months price to earnings ratio of 1.61. meaning, the purchaser of the share is investing €1.61 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.04%.

revenue growth

year-on-year quarterly revenue growth declined by 13.7%, now sitting on 640.29m for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, crcam brie pic2cci's stock is considered to be overbought (>=80).

volume

today's last reported volume for crcam brie pic2cci is 1883 which is 53.9% below its average volume of 4085.

more news about crcam brie pic2cci.

2. tinc (tinc.br)

4.52% forward dividend yield and 6.13% return on equity

tinc comm. va is an investment firm specializing in investments in public and private infrastructure, real assets, and energy sector. tinc comm. va is based in antwerpen, belgium.

earnings per share

as for profitability, tinc has a trailing twelve months eps of €0.79.

pe ratio

tinc has a trailing twelve months price to earnings ratio of 15.32. meaning, the purchaser of the share is investing €15.32 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.13%.

yearly top and bottom value

tinc's stock is valued at €12.10 at 07:30 est, way under its 52-week high of €13.80 and above its 52-week low of €11.90.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on oct 24, 2022, the estimated forward annual dividend rate is 0.54 and the estimated forward annual dividend yield is 4.52%.

more news about tinc.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,285 source documents archived
Query this data → isubstrate.com